On Tuesday, the Federal Trade Commission (FTC) released its second interim staff report on prescription drug middlemen. The report examines the impact of PBMs (specifically CVS Caremark ...
The lawsuit claims that three major healthcare companies were pushing up the price of insulin by 1,200 percent.
The Federal Trade Commision (FTC) found prescription benefits managers like UnitedHealth's OptumRX have gained $7.3B from ...
Pharmacy benefit managers overcharged for specialty generic medications — in many cases by hundreds and thousands of percent ...
Shocking revelations from a Federal Trade Commission, or FTC, investigation have exposed how three major prescription benefit managers, or PBMs, ...
The FTC analyzed data for 51 specialty generic drugs dispensed from 2017-2022 for patients with commercial insurance or Medicare Part D plans managed by CVS Caremark, Express Scripts and OptumRx.
The term Web Client Runtime Security (WCRS) was coined by the authors to highlight the security or possible malicious behavior of the code executed in users' browsers during their web interactions.
The FTC report showed that from 2017 to 2022, the three PBMs—UnitedHealth Group's Optum, CVS Health's CVS Caremark and Cigna's Express Scripts—marked up prices at their pharmacies by hundreds ...
The latest report accuses the PBMs — CVS Caremark, Optum Rx ... according to the FTC. Specifically, the companies were able to generate more than $7.3 billion in revenue by dispensing medicines ...
In 2021, the FDA approved a new insulin drug, Semglee, that was interchangeable with a brand-name insulin called Lantus.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback